Currently, there are many clinical trials employing PI3K inhibitors as monotherapies against solid tumors, including a phase II clinical trial utilizing the p110γ inhibitor IPI-549 on locally advanced HNSCC [5,16]. Here, PIK3CD is linked to head and neck squamous cell carcinoma.